Varex Imaging (VREX) Jefferies 2024 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies 2024 Global Healthcare Conference summary
1 Feb, 2026Market overview and growth drivers
Serves nearly all global X-ray OEMs, with high customer retention over decades.
Healthcare segment grows 2%-4% annually, driven by population growth, aging, and new technologies.
Industrial segment represents 25% of sales, growing 6%-8% annually, leveraging healthcare tech for new applications.
Industrial growth fueled by greenfield X-ray applications in oil & gas, food inspection, and automotive.
Current market pressures and outlook
Medical segment down mid-teens in H1, impacted by China’s anti-corruption campaign and global inventory adjustments.
Inventory destocking expected to last 6-9 months; some improvement anticipated by year-end.
China, about 14% of revenue, expected to recover gradually post-campaign, with potential pent-up demand.
Recovery pace in China depends on macro conditions, anti-corruption progress, and stimulus rollout.
Competitive landscape and industry trends
Minimal competition in X-ray sources; some competition in detectors, mainly static, but limited revenue exposure.
Industry trend favors outsourcing over insourcing, with increasing OEM specialization and demand for focused solutions.
Scale and R&D focus enable delivery of innovative, cost-effective X-ray components.
Latest events from Varex Imaging
- Stable demand, India expansion, and photon counting tech position for growth amid policy uncertainty.VREX
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Stable demand, India ramp-up, and photon counting drive growth and margin outlook.VREX
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - All board nominees, executive pay, and auditor ratification were approved by stockholders.VREX
AGM 202612 Feb 2026 - Revenue up 5% to $210M, 90% EPS growth, strong industrial momentum, and positive Q2 outlook.VREX
Q1 202611 Feb 2026 - Revenue beat guidance, but a $93.9M goodwill impairment led to a GAAP net loss.VREX
Q3 20253 Feb 2026 - Photon counting tech, China recovery, and debt reduction drive 2025 outlook amid trade risks.VREX
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Revenue down 9.9% year-over-year; Medical weak, Industrial up, Q4 outlook cautious.VREX
Q3 20242 Feb 2026 - Investments in India, photon counting, and cargo systems set up strong multi-year growth.VREX
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference14 Jan 2026 - Q4 revenue was $206M, with strong Industrial results and a 12% Medical segment decline.VREX
Q4 202413 Jan 2026